Arca
Skip to content
Tools
Tools

Seasonal allergic rhinitis

Drug research and approvals for seasonal allergic rhinitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 19 studies of seasonal allergic rhinitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 19
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting now

Newest posted first, of 19 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 38

Phase 3 12 of 14

Phase 2 12 of 23

Phase 1 or earlier 12 of 13

How its trials ended

375 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 115 whose ending is known, 80% met their primary endpoint, 10% missed it and 10% stopped early.

  • Completed, result not reported22660%
  • Met its primary endpoint9225%
  • Ongoing195%
  • Status unknown154%
  • Missed its primary endpoint113%
  • Stopped: enrollment or feasibility72%
  • Stopped: sponsor or business decision21%
  • Stopped: other or unclear21%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 15; search them all in Canada trials
Nov 13, 2026Follow-up to a phase 2 trial to evaluate the safety and immunological effects of short-course DM-101PX in adults with birch pollen-induced allergic rhinitis or…DM-101PXDesentum OyPending
Dec 31, 2025A randomized, double-blind, placebo-controlled, environmental exposure unit trial of intranasal INI-2004 in subjects with ragweed-induced allergic rhinitisINI-2004Inimmune CorporationClosed
Oct 23, 2025A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety of lebrikizumab in adult and…Lebrikizumab (LY3650150) / AzelastineEli LillyOngoing
Aug 26, 2025A two-part, adaptive, double-blind, randomized, placebo-controlled, study to assess the appropriate dose and the appropriate dosing frequency of aldp 001 in…Alcaftadine (ALDP001)Alixer Nexgen Therapeutics LtdClosed
May 24, 2023An open-label, single-dose, three-way crossover study to compare the pharmacokinetics of fixed-dose combination of mometasone + azelastine nasal spray to…Azelastine-mometasone / Azelastine / MometasoneSandozClosed
Nov 30, 2022A phase IIIb, single-center, double-blind, two-arms, placebo-controlled, randomized, parallel-group clinical trial to evaluate the efficacy and safety of 2-day…Fexofenadine (M016455)Opella Healthcare Group SASClosed
Jul 25, 2022A two-part randomized, double-blind, placebo-controlled study to assess the efficacy of the anti-bet v 1 monoclonal antibodies to reduce allergic rhinitis and…REGN5713 / REGN5714 / REGN5715RegeneronClosed
Mar 5, 2021Efficacy and safety of the sq tree sublingual immunotherapy tablet in children and adolescents (5 through 17 years of age) with moderate to severe allergic…ItulatekALK-AbellóClosed
Dec 22, 2020A phase 3 randomized, double-blind, placebo-controlled study assessing the efficacy of anti-bet v 1 monoclonal antibodies to reduce symptoms of seasonal…REGN5713-5714-5715RegeneronClosed
Oct 26, 2018A randomized, double-blind, placebo controlled study to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in adult subjects with…HAL-MRE1Hal Allergy BVPending

Medicines authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Jul 30, 2007AerinazeDesloratadine; pseudoephedrineOrganon N.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.